Id genes and proteins as promising targets in cancer therapy.
Since the identification of Id proteins more than a decade ago, much work has demonstrated their regulatory roles in development, cell fate and lineage determination, proliferation, differentiation, angiogenesis, invasion and migration. Recent studies reveal not only that Id protein expression is significantly correlated both with cancer progression and with overall prognosis, but also that it can be exploited as a therapeutic target. This review will focus on the recent advances in our understanding of the relationships between Id expression and cancer, as well as providing a rationale for developing therapeutic strategies using Ids as targets to treat metastatic cancers.
California Pacific Medical Center Research Institute, San Francisco, CA 94115, USA.
Sylvia
S
Fong
Robert J
RJ
Debs
Pierre-Yves
PY
Desprez
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018257:Helix-Loop-Helix Motifs; D006801:Humans; D051798:Inhibitor of Differentiation Protein 1; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism*; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*
D000970:Antineoplastic Agents; C497453:ID1 protein, human; D051798:Inhibitor of Differentiation Protein 1; D012097:Repressor Proteins; D014157:Transcription Factors